Latest News

STAT Plus: Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy

CAMBRIDGE, Mass. — Days before his company is expected to win approval of the most expensive drug ever, the head of Swiss drug giant Novartis said Wednesday he could justify charging up to $5 million for the revolutionary treatment for a rare genetic disease, but it will end up being priced at a fraction of that.

Speaking at the company’s biomedical research institute, Novartis CEO Vas Narasimhan wouldn’t disclose the price of the drug, called Zolgensma, until the government approves it, probably by the end of the month. Zolgensma treats spinal muscular atrophy, or SMA, a deadly neurodegenerative disease.

Continue to STAT Plus to read the full story…

Source link




Related posts

Driver gene mutations found to be common for cancer metastases

Newsemia

Surgical Electricity Used to Molecularly Reshape Tissues

Newsemia

AcQMap Heart Mapping Technology Gets EU and US Green Lights

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy